Early statin therapy in elderly patients presenting with acute coronary syndrome causing less heart failure

Indian Heart Journal

Volumn 58, Issue 4, 2006, Pages 321-324

  Saab, Fadi A ^a   Petrina, Mircea ^a   Kline Rogers, Eva ^a   Fang, Jianming ^a   Otten, Richard ^a   Mukherjee, Debabrata ^b   Eagle, Kim A ^a,c  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c Cardiovascular Center   (United States)

Author keywords

Acute coronary syndrome; Elderly patients; Outcomes; Statin therapy

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE CORONARY SYNDROME; AGED; ARTICLE; COMORBIDITY; CONTROLLED STUDY; FEMALE; HEART FAILURE; HEART INFARCTION; HUMAN; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; MORTALITY; RECURRENT DISEASE; STROKE;

ACUTE CORONARY SYNDROME; AGED; AGED, 80 AND OVER; FEMALE; HEART FAILURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOGISTIC MODELS; MALE; PROSPECTIVE STUDIES;

EID: 33845456137     PISSN: 00194832     EISSN: 00194832     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. The Heart Protection Study Group. The MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: randomized placebo controlled trial. Lancet 2002;360:7-22.
2. De Lemos JA, Blazing MA, Braunwald, et al. A to Z Investigators. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004;292:1307-16.
3. Rosamond WD, Chambless LE, Folsom AR, Cooper LS, Conwill DE, Clegg L. Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease.1987 to 1994. N Engl J Med 1998;339:861-67.
4. Heart and Stroke Statistical Update (2001). American Heart Association, Dallas, Tex.
5. Nissen SE, Tuzcu EM, Ganz P, et al. Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators. Statin therapy, LDL cholesterol, C-reactive protein and coronary artery disease. N Engl J Med 2005;352:29-38.
6. Ridker PM, Cannon CP, Braunwald E, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352:20-28.
7. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-43.
8. Ridker PM, Rifai N, Pfeffer MA. Inflamation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. The cholesterol and recurrent events (CARE) trial. Circulation 1999;98:839-44.
9. Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL. Cytokines and cytokine receptors in advanced heart failure. Circulation 2001;103:2055-59.
10. Rauchhaus M, Doehner W, Francis DP. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 2000;102:3060-67.
11. Schwartz GG, Olsson AG, Stern T, et al. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001;285:1711-18.
12. Treasure CB, Klein JL, Weintraub WS. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995;332:481-87.
13. Wolfrum S, Dendorfer A, Richardt G, et al. Simvastatin acutely reduces myocardial reperfusion injury in vivo by activating the phosphatidylinositide 3-kinase/akt pathway. J Cardiovas Pharmacol 2004;44:348-55.
14. Dupuis J, Tardif JC, Cernacek P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE trial. Circulation 1999;99:3227-33.
15. Katz SD, Khan T, Zeballos G. Decreased activity of L-arginine-nitric oxide metabolic pathway in patients with congestive heart failure. Circulation 1999;99:2113-17.
16. Vaughan CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet 1996;348:1079-82.
17. Remme WJ. Overview of relationship between ischemia and congestive heart failure. Clin Cardiol 2000;23:4-8.
18. Cohn JN, Johnson GR, Shabetai R. Mechanism data from the VA cooperative studies. Circulation 1993;86:5-16.
19. Pliquett RU, Conish KG, Peuler JD, Zucker IH. Simvastatin normalizes autonomic neural control in experimental heart failure. Circulation 2003;107:2493-98.
20. Pliquett RU, Conish KG, Peuler JD, Zucker IH. Statin therapy restores sympathovagal balance in experimental heart failure. J Appl Physiol 2003;95:700-04.
21. Shipley MJ, Pocock SJ, Marmot HG. Does plasma cholesterol concentration predict mortality from coronary heart disease in elderly people? 18-year follow-up in the Whiteball Study. BMJ 1991;303:89-92.
22. Weverling-Rijnsburger AW, Blauw GJ, Lagaay AM, Knook DL, Meinders AE, Westendorp RG. Total cholesterol and risk of mortality in the oldest old. Lancet 1997;350:1119-23.
23. Schatz IJ, Masaka K, Yano K, Chen R, Rodriguez BL, Curb JD. Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: a cohort study. Lancet 2001;358:351-55.
24. Shepherd J, Blauw GJ, Westendorp RG, et al. PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk. Lancet 2002;360:1623-30.
25. Ganz DA, Kuntz KM, Jacobson GA, Avorn J. The cost effectiveness of HMG CO-A reductase inhibitors therapy in older patients with myocardial infarction. Ann Intern Med 2000;132:780-87.